[Immunotherapy with Solco Urovac vaccine in chronic genitourinary infection].
Twenty five patients with chronic urogenital infections (cystitis, pyelitis and prostatitis) were treated with Solco urovak infection which is active against Escherichia coli, Proteus, Klebsiella and Streptococcus fecalis organisms. This microbial flora has been isolated from these patients and proved resistant to the conventional antibacterial agents. The vaccine was very well tolerated, gave no side reactions, but transient short lasting rise of the temperature to 38 degrees C. The bacteriologic control on the 6. week after vaccination showed sterile urine in 68 per cent of the patients, no change in 20 per cent and recovery of other bacterial flora in 12 per cent. The vaccine is recommended for treatment of urinary tract infections caused by the microorganisms enumerated above.
Donovski
L
L
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D001419:Bacteria / Q000302:isolation & purification; D001424:Bacterial Infections / Q000382:microbiology / Q000628:therapy*; D001428:Bacterial Vaccines / Q000627:therapeutic use*; D003556:Cystitis / Q000382:microbiology / Q000628:therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D011472:Prostatitis / Q000382:microbiology / Q000628:therapy; D011702:Pyelitis / Q000382:microbiology / Q000628:therapy; D013997:Time Factors; D014552:Urinary Tract Infections / Q000382:microbiology / Q000628:therapy*
D000276:Adjuvants, Immunologic; D001428:Bacterial Vaccines; C055507:SolcoUrovac
Imunoterapiia s vaktsinata Solco Urovac na khronichnata genitourinarna infektsiia.